ISSN: 1859 - 2872
Efficacy and safety of add-on dapagliflozin therapy in patients with type 2 diabetes
Main Article Content
Keywords
Abstract
Objective: To evaluate the efficacy and safety of add-on dapagliflozin 10mg in type 2 diabetes. Subject and method: A cross-sectional study, follow-up for 12 weeks, comparing before and after treatment on 124 patients with type 2 diabetes, outpatient treatment at 108 Military Central Hospital from 12/2021 to 4/2022, with HbA1c level 7%-10%, on at least 1 OAD previous, supplemented with dapagliflozin 10mg. All patients were clinically examined and tested at the time of drug supplementation and after 12 weeks. Result: After 12 weeks of additional treatment: HbA1c by -0.54% (95% confidence interval [CI]: -0.64, -0.44, p<0.001), FPG was -1.12mmol/l (CI 95%: -0.77, -1.44; p<0.001) body weight was -1.0kg (CI 95%: -1.35, -0.69, p<0.001)), and systolic/diastolic blood pressure by -3.6/-1.4mmHg. The proportion of patients achieving HbA1c < 7% target was 13.7%, the proportion of patients who were poorly controlled (HbA1c > 8%) decreased from 62.1% at baseline to 33.1% at 3 months, 62.3% of patients showed simultaneous reductions in HbA1c and body weight. Adverse events: 6.5% patients had mild symptoms of hypoglycemia, mainly in patients taking > 3 hypoglycemic drugs, 6.5% had genital tract infection, twice as many women as men, 8.1% had urinary tract infections. Diabetic ketoacidosis, hyperosmolarity, or amputation did not occur during the treatment period. Conclusion: Add-on therapy with dapagliflozin 10mg significantly improves glycemic control, body weight and blood pressure in patients with type 2 diabetes.
Article Details
References
2. American Diabetes Association (2022) Standards of medical care in diabetes 2022. Diabetes care.
3. Wiviott SD, Raz I, Bonaca MP et al (2018) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4): 347-357.
4. Skolnik N, Bonnes H, Yeh H et al (2016) Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C. Postgrad Med 128(4): 356-363.
5. Fioretto P, Mansfield TA, Ptaszynska A et al (2016) Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies. Drugs Aging 33(7): 511-522.
6. Bolinder J, Ljunggren O, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab16(2): 159-169.
7. Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, Chen L (2018) Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(2): 458-462.
8. Jabbour S, Seufert J, Scheen A et al (2018) Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20(3): 620-628.
9. Tokushige K, Ikejima K et al (2021) Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol 56(11): 951-963.
Article Sidebar
